These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
329 related items for PubMed ID: 22490714
1. [Sirolimus use in heart transplantation recipients with chronic renal dysfunction]. Yin D, Huang J, Feng L, Liao ZK, Feng GX, Wang W, Song YH, Hu SS. Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Feb; 40(2):136-40. PubMed ID: 22490714 [Abstract] [Full Text] [Related]
2. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity. Kushwaha SS, Khalpey Z, Frantz RP, Rodeheffer RJ, Clavell AL, Daly RC, McGregor CG, Edwards BS. J Heart Lung Transplant; 2005 Dec; 24(12):2129-36. PubMed ID: 16364861 [Abstract] [Full Text] [Related]
3. Sirolimus experience in heart transplantation. Aranda-Dios A, Lage E, Sobrino JM, Mogollón MV, Guisado A, Cabezón S, Hinojosa R, Hernández A, Ordóñez A. Transplant Proc; 2006 Oct; 38(8):2547-9. PubMed ID: 17097997 [Abstract] [Full Text] [Related]
7. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency. Yang YJ, Chen DZ, Li LX, Kou JT, Lang R, Jin ZK, Han DD, He Q. Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147 [Abstract] [Full Text] [Related]
8. Calcineurin inhibitor substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients. Potter BJ, Giannetti N, Edwardes MD, Cecere R, Cantarovich M. Clin Transplant; 2007 Jun; 21(3):305-8. PubMed ID: 17488377 [Abstract] [Full Text] [Related]
9. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination. Cataneo-Dávila A, Zúñiga-Varga J, Correa-Rotter R, Alberú J. Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355 [Abstract] [Full Text] [Related]
10. [Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: a 4-year prospective study]. Huang HF, Wu JY, Han F, Wang YM, Zhang JG, Chen JH. Zhonghua Yi Xue Za Zhi; 2011 Dec 27; 91(48):3397-400. PubMed ID: 22333250 [Abstract] [Full Text] [Related]
11. Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients. Groetzner J, Kaczmarek I, Landwehr P, Mueller M, Daebritz S, Lamm P, Meiser B, Reichart B. Eur J Cardiothorac Surg; 2004 Mar 27; 25(3):333-41. PubMed ID: 15019657 [Abstract] [Full Text] [Related]
12. Renal function improvement after conversion to proliferation signal inhibitors during long-term follow-up in heart transplant recipients. Kaplinsky E, González-Costello J, Manito N, Roca J, Barbosa MJ, Nebot M, Salazar-Mendiguchia J, Berdejo J, Mañas P, Miralles A, Cequier A. Transplant Proc; 2012 Nov 27; 44(9):2564-6. PubMed ID: 23146455 [Abstract] [Full Text] [Related]
13. Early renal benefit of rapamycin combined with reduced calcineurin inhibitor dose in pediatric heart transplantation patients. Balfour IC, Srun SW, Wood EG, Belsha CW, Marshall DL, Ferdman BR. J Heart Lung Transplant; 2006 May 27; 25(5):518-22. PubMed ID: 16678029 [Abstract] [Full Text] [Related]
14. Recovery of renal function in heart transplantation patients after conversion from a calcineurin inhibitor-based therapy to sirolimus. Ayub-Ferreira SM, Avila MS, Feitosa FS, Souza GE, Mangini S, Marcondes-Braga FG, Issa VS, Bacal F, Chizzola PR, Cruz FD, Bocchi EA. Transplant Proc; 2010 Mar 27; 42(2):542-4. PubMed ID: 20304188 [Abstract] [Full Text] [Related]
15. Anti-CD25 monoclonal antibody replacement therapy for chronic kidney disease in liver transplant recipients. Walsh C, Barkun J, Tchervenkov J, Deschenes M, Ghali P, Wong P, Chaudhury P, Paraskevas S, Metrakos P, Cantarovich M. Transplantation; 2013 Feb 15; 95(3):495-500. PubMed ID: 23296149 [Abstract] [Full Text] [Related]
16. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients. Sundberg AK, Rohr MS, Hartmann EL, Adams PL, Stratta RJ. Clin Transplant; 2004 Feb 15; 18 Suppl 12():61-6. PubMed ID: 15217410 [Abstract] [Full Text] [Related]
17. Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure. Groetzner J, Meiser B, Landwehr P, Buehse L, Mueller M, Kaczmarek I, Vogeser M, Daebritz S, Ueberfuhr P, Reichart B. Transplantation; 2004 Feb 27; 77(4):568-74. PubMed ID: 15084937 [Abstract] [Full Text] [Related]
18. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ. Liver Transpl; 2003 Oct 27; 9(10):1079-85. PubMed ID: 14526403 [Abstract] [Full Text] [Related]
19. Conversion to everolimus in kidney transplant recipients: to believe or not believe? Cotovio P, Neves M, Santos L, Macário F, Alves R, Mota A. Transplant Proc; 2012 Dec 27; 44(10):2966-70. PubMed ID: 23195007 [Abstract] [Full Text] [Related]
20. Early sirolimus therapy in renal transplant recipients at high risk: is it justified? Halim MA, Al-Otaibi T, Johny KV, Hamid MH, Al-Waheeb S, Hasaneen H, Awadain WH, Nawas KM, El-Sayed A, Said T, Nair MP, Nampoory MR. Transplant Proc; 2009 Sep 27; 41(7):2784-8. PubMed ID: 19765435 [Abstract] [Full Text] [Related] Page: [Next] [New Search]